REPL Tudriqev: $450K Melanoma Launch at $1.46B Cap

Replimune became a commercial-stage company on August 6, and the market has spent three weeks trying to decide what that is worth. The stock closed at $12.86 on approval day, up 9% from the $11.83 prior close, then ran to $15.50 by August 28, a 31% gain from the pre-approval close and a $1.46 billion market cap. The move is not euphoria. It is the market slowly pricing in the fact that Tudriqev, the first oncolytic virus approved for melanoma, now has a real price tag, a real sales force, and a real shot at a niche nobody has successfully claimed. The question is whether that shot is a franchise or a footnote.

What got approved, and what it actually means. Tudriqev (vusolimogene oderparepvec-wtpg, formerly RP1) won accelerated approval in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed on an anti-PD-1 regimen. It arrived on the third attempt, after Complete Response Letters in July 2025 and April 2026 and a contentious 10-3 adcomm vote that followed briefing documents calling the IGNYTE data not interpretable. The label rests on the IGNYTE registrational cohort: 140 patients enrolled, 91 efficacy-evaluable, with an objective response rate of 24.2% and a median duration of response of 14.1 months. The population was genuinely high-risk, with 80% Stage 4 disease, 54% PD-L1 negative, and 24% liver metastases, a known negative prognostic factor in melanoma. That is a meaningful number in a group that faces a median overall survival of under one year after checkpoint failure. But it is also a single-arm number, which is precisely why the confirmatory IGNYTE-3 trial (NCT06264180) now carries the entire franchise on its shoulders.

Commercial reality: the price is a statement. Replimune set Tudriqev’s list price at $450,000 per course, before rebates, with the caveat that dosing scales to tumor burden. That number is a deliberate undercut of Iovance’s Amtagvi, the tumor-infiltrating lymphocyte therapy priced at $515,000 per patient, and it is a bet that payers will treat an intratumoral injection as more palatable than a 22-day ex vivo manufacturing chain. The mechanics are not trivial: Tudriqev is an HSV-1 virus engineered to delete the ICP34.5 and ICP47 genes and carry a fusogenic glycoprotein plus GM-CSF, injected directly into superficial and, under imaging guidance, visceral lesions. That is a procedural burden a checkpoint antibody never has. The launch is funded: an August 11 offering raised $150 million gross, roughly $141 million net, at $12.06 per share across 9.7 million shares plus pre-funded warrants, and management says the balance plus existing cash funds operations for more than 12 months. The raise was well-timed. Buyers at $12.06 are up about 28% in three weeks. Dilution is real but absorbed.

The patient funnel, and the ghost in the room. Melanoma produces roughly 105,000 new US cases a year, and more than half of patients progress within six months of checkpoint therapy. That implies a refractory pool on the order of 10,000 to 12,000 patients annually, the same pool Iovance (IOVA) is monetizing at a $99.3 million quarterly revenue run rate, with Amtagvi generating about $91 million of it and gross margins now at 56%. At $450,000 per course, capturing even 1,000 of those patients a year is $450 million of gross revenue before rebates, which is why the class keeps attracting capital despite T-VEC’s failure. Iovance grew 66% year over year and 39% sequentially, proof that a therapy with a heavy logistical lift can still scale if the clinical need is real. Tudriqev has two structural edges: a broader label that covers BRAF-naive and pretreated patients and adjuvant-relapsed patients, and no per-patient manufacturing bottleneck, because the virus is injected, not manufactured in a 22-day loop. The ghost is Imlygic, Amgen’s T-VEC, the first oncolytic virus, approved in 2015 and quietly abandoned as a commercial afterthought. The lesson of T-VEC is that a niche approval does not automatically become a niche business. Replimune has to prove its virus sells where T-VEC’s never did.

The differentiation question is fair: why would an oncologist reach for an intratumoral injection when checkpoint antibodies are already the standard? The answer is that these patients have already failed a checkpoint, and Tudriqev’s entire thesis is that a virus injected directly into a tumor can reignite an immune response that the exhausted checkpoint pathway no longer triggers. That is also the answer to the bear who calls 24.2% weak: in a post-PD-1 population where the alternative is a median survival under a year, a 14.1-month median duration of response is a real improvement, not a rounding error.

The franchise question. The bull case is that Tudriqev is not T-VEC. It is dosed in combination with nivolumab in the post-PD-1 setting, a population with an actual unmet need, and its 24.2% response rate with a 14.1-month duration landed in a population Iovance is treating at a higher price and a higher logistical burden. If early scripts show oncologists and interventional radiologists actually adopting intratumoral injection, the $1.46 billion cap looks cheap against a $450,000 per course price. The bear case is that 24.2% is a modest response rate, the single-arm design means the FDA’s two prior rejections were not paranoid, and safety is not frictionless: serious adverse reactions occurred in 35% of patients, and the label carries warnings for herpetic infection, visceral injury, and accidental exposure. The confirmatory IGNYTE-3 trial, randomizing against physician’s choice where over 90% receive Opdualag, has to hold up. That readout lands in 2027, and until it does, every dollar of the current valuation rests on unverified launch momentum. IGNYTE-3 is also a materially higher bar than the single-arm number that got the drug approved: it must show a survival or progression benefit against physician’s choice, not just a response rate. Between now and then, the stock trades on two things: early prescription data from the launch, and the September ESMO data update from Iovance that will reset the bar for the entire refractory-melanoma niche. If Amtagvi’s ESMO numbers disappoint, the whole pool gets repriced, and Replimune would feel it harder than Iovance because Replimune has no revenue to cushion the fall.

The valuation, checked against the only comp that matters. Replimune is a pre-revenue company trading at $1.46 billion. Iovance, the only other company monetizing this exact refractory-melanoma pool, is worth $3.63 billion on $99.3 million of quarterly revenue and $350 million to $370 million of 2026 guidance, roughly 10 times forward sales, and it is growing 66% year over year. The market is paying Replimune about 40% of Iovance’s price for a company with zero revenue and a smaller claim on the patient funnel. That is the pre-revenue premium in action: the market is already paying for launch success it has not seen. The gap closes only if Tudriqev’s scripts ramp the way Amtagvi’s did, which is why the first two quarters of commercial data, not the approval, are the real test.

The verdict. The position here is small, not a conviction one. The approval is real, the financing is done, and the price undercut plus the broader label give Tudriqev a genuine lane against Amtagvi. But the oncolytic virus class has exactly one cautionary tale and zero commercial successes, and a 24.2% single-arm response rate does not erase that history. Size this at 1% to 2% of a portfolio and watch the first two quarters of script data. If launch numbers come in north of the early Iovance trajectory, add. If IGNYTE-3 confirms in 2027, the franchise question is answered and the stock re-rates hard. If either wobbles, $1.46 billion is a lot to pay for a footnote.